Amol Akhade

Amol Akhade: B7-H4 ADCs Emerge as New Hope in Breast Cancer

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X:

“New data from ESMO Breast 25
B7-H4 ADCs emerge as new hope in breast cancer!
  • Puxitatug Samrotecan in HR+/HER2– mBC (Topo1i-naïve)
  • B7-H4+ in 45%
  • ORR: 40% (1.6 mg/kg)
  • Low ILD and discontinuation
  • HER2-low? Biomarker timing?
Emiltatug Ledadotin in B7-H4 high TNBC (Topo1i-pretreated)
  • ORR: 23% overall | 29% in ≤4 prior lines
  • 0% response in B7-H4 low
  • PFS: 16 wks (B7-H4 high) vs 6.4 wks (low)
  • Manageable toxicity
Takeaway
B7-H4 expression matters.
Next-gen ADCs may still shine post-TROP2/HER2 failures!Amol Akhade: B7-H4 ADCs Emerge as New Hope in Breast Cancer

More posts featuring Amol Akhade.

Amol Akhade Breast Cancer cancer ESMOBreast25 OncoDaily Oncology TNBC